Unresectable Esophageal Squamous Cell Carcinoma
Drug | Drug Name | Drug Description |
---|---|---|
DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
DB14922 | Tislelizumab | An IgG4 variant monoclonal antibody against PD-1 indicated for the treatment of unresectable, locally advanced or metastatic esophageal squamous cell carcinoma |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB09035 | Nivolumab | Programmed cell death protein 1 | target |
DB09035 | Nivolumab | Programmed cell death 1 ligand 1 | target |
DB14922 | Tislelizumab | Programmed cell death protein 1 | target |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB11740 | Adavosertib | 1 | Active Not Recruiting | 1 |
DB16680 | Cadonilimab | 2 | Not Yet Recruiting | 1 |
DB00515 | Cisplatin | 2 | Not Yet Recruiting | 1 |
DB09035 | Nivolumab | 2 | Recruiting | 1 |
DB01229 | Paclitaxel | 2 | Not Yet Recruiting | 1 |